



# Biotech Daily

Tuesday March 28, 2017

*Daily news on ASX-listed biotechnology companies*

- \* **ASX UP, BIOTECH EVEN: ITL UP 10.5%, PRANA DOWN 8%**
- \* **TGA APPROVES LBT PLATE ASSESSMENT FOR REGISTER**
- \* **ONCOSIL RECRUITS 1<sup>st</sup> PANCREATIC CANCER PATIENT**
- \* **ITL CLAIMS FEBRUARY 'RECORD REVENUE, PROFIT MONTH'**
- \* **NOVOGEN RECEIVES \$4.4m FEDERAL R&D TAX INCENTIVE**
- \* **SINGAPORE PATENT FOR ORTHOCELL CELGRO COLLAGEN SCAFFOLD**
- \* **CHINA PATENT FOR REGENEUS STEM CELL ACNE TREATMENT**
- \* **MACH7 TO RELEASE 44.2m ESCROW, 24m PERFORMANCE SHARES**
- \* **PRESCIENT PLEADS SCHULTZ TO ASX 9% QUERY**
- \* **FIL TAKES 8% OF RESAPP**
- \* **ZELDA REQUESTS 'CAPITAL RAISING' TRADING HALT**
- \* **UNILIFE LOSES V-P, CCO MICHAEL RATIGAN**

## MARKET REPORT

The Australian stock market climbed 1.3 percent on Tuesday March 28, 2017, with the ASX200 up 74.5 points to 5,821.2 points. Fifteen of the Biotech Daily Top 40 stocks were up, 15 fell, eight traded unchanged and two were untraded. All three Big Caps were up.

ITL was the best on an unspecified record month, up 4.5 cents or 10.5 percent to 47.5 cents with 387,795 shares traded. Mesoblast climbed 9.4 percent; Oncosil was up 6.3 percent; Clinuvel, Compumedics, Living Cell, Pro Medicus and Viralytics improved more than four percent; Actinogen, Benitec and Orthocell were up more than three percent; Airxpanders and Uscom rose more than two percent; Nanosonics and Sirtex were up more than one percent; with Cochlear, CSL and Resmed up by less than one percent.

Prana led the falls, down 0.4 cents or eight percent to 4.6 cents with 43,940 shares traded. Cellmid and Opthea lost more than five percent; Acrux, Atcor, Neuren and Prima fell more than three percent; Avita, Bionomics and Impedimed shed two percent or more; Factor Therapeutics and Osprey were down more than one percent; with Cyclopharm, Ellex and Reva down by less than one percent.

## LBT INNOVATIONS

LBT says that all models of its automated plate assessment system (APAS) have been included on the Australian Register of Therapeutic Goods.

LBT said that, through its Clever Culture Systems AG joint venture, the Therapeutic Goods Administration included the APAS on the register as an in-vitro diagnostic device.

The company said that inclusion on the register was “an important milestone to support the sale and distribution of APAS products” in Australia.

LBT chief executive officer Brent Barnes said that inclusion on the register was “part of the global distribution strategy ... in preparation of bringing product to market”.

Mr Barnes said that the APAS was granted US Food and Drug Administration clearance in October 2016 “based on an extensive independent 10,000-patient clinical study across two continents and supported by peer review publications”.

LBT said that APAS was “a global first for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation ... [enabling] faster diagnosis and reporting of infection and disease”.

The company said that the technology was “at least three times more efficient than manual plate reading and meets the market need for helping with increased workloads, quality demands and decreasing budgets”.

LBT was up four cents or 14.3 percent to 32 cents with 1.5 million shares traded.

## ONCOSIL MEDICAL

Oncosil says that Monash Health has recruited the first of 20 patients in its pancreatic cancer trial.

Oncosil said the patient would begin one month of chemotherapy prior to implantation with the radioactive Brachysil device.

The company said the trial was directed to Conformité Européenne (CE) mark approval and was required for a supplemental data request from the British Standards Institute.

Oncosil said that 16 centres had confirmed they would participate in the pancreatic cancer study program, with Sydney’s St Vincent’s Hospital expected to begin recruiting patients in the coming weeks.

Oncosil was up half a cent or 6.3 percent to 8.4 cents.

## ITL HEALTH GROUP

ITL Health says that its revenue and profit for the month of February 2017 were the highest in its 23-year history.

ITL did not disclose the amount of revenue but said that in the six months to December 31, 2016 it had revenue of \$17,474,000 with net profit after tax of \$2,117,000, equating to an average revenue of \$2,912,333 a month and profit of \$352,833 a month.

The company said that both its bio-medical and healthcare divisions had record months.

ITL said the healthcare division had an increase in sales of its intra-venous IV Starter Kit and the bio-medical sector began the supply of products under the Biomérieux distribution agreement for its Samplok blood sampling kit (BD: Oct 17, 2016).

The company said it expected “a strong result for the full financial year even allowing for some seasonality in the second half year”.

ITL executive chairman Bill Mobbs said the February sales included some initial stocking up, but “we are confident that this is the first step in the anticipated growth of [the Samplok sampling kit] sales in the future”.

ITL was up 4.5 cents or 10.5 percent to 47.5 cents.

## NOVOGEN

Novogen says it has received \$4,436,284 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Novogen said the rebate related to research and development expenditure for the year to June 30, 2016.

The company said the funds would be used to support its on-going clinical programs, primarily to progressing trials of Cantrixil and GDC-0084.

Novogen fell 0.1 cents or 1.4 percent to 6.9 cents with 1.4 million shares traded.

## ORTHOCELL

Orthocell is pleased to announce it has been granted a further Singapore patent for Celgro collagen-based medical device for soft tissue regeneration applications.

Orthocell said that the patent, entitled 'Method for Producing a Collagen Membrane and Uses Thereof' provided important additional intellectual property protection for the Celgro product platform until 2033.

Orthocell managing-director Paul Anderson said the patent was "an important addition to our current Singapore patent covering Celgro and further strengthens our international patent position for our soft tissue regeneration platform technology".

The company said that Celgro was developed to address problems with existing bio-derived scaffolds and had superior tissue in-growth repair qualities, while exhibiting strong mechanical properties, which could be tuned to accommodate the needs of the specific tissue repair.

Orthocell said it had submitted Celgro for first regulatory approval in Europe, with the company awaiting final Conformité Européenne (CE) mark approval.

The company said it had submitted a US Food and Drug Administration 510(k) application.

Orthocell was up 1.5 cents or 3.8 percent to 41 cents.

## REGENEUS

Regeneus says that China has granted its first patent, covering the use of its stem cell secretions technology for the topical treatment of acne.

Regeneus said that China's State Intellectual Property Office granted a patent, entitled 'Use of a composition comprising adipose tissue-derived secretions in the manufacture of a medicament for topical treatment or prevention of acne in a subject', which would provide commercial rights in China to March 15, 2032.

The company said the secretions technology used the molecules, including exosomes, cytokines and growth factors, secreted by mesenchymal stem cells.

Regeneus said that skin conditions and wound healing were one of the most promising and near-term areas for cell-based regenerative medicine products.

The company said that there were few treatment innovations or improvements in the treatment of acne over the last 10 years and the demand for new improved acne treatments was high.

Regeneus said the global market for acne prescription treatments was more than \$US3 billion a year.

The company said it had additional patent applications that covered the use of the secretions technology for other skin conditions.

Regeneus was unchanged at 14.5 cents.

### [MACH7 TECHNOLOGIES](#)

Mach7 says it will release 44,193,300 shares and 24,047,282 performance shares from escrow on April 8, 2017.

Mach7 said the performance shares consisted 14,428,370 class A performance shares, 4,809,456 class B performance shares and 4,809,456 class D performance shares, and would remain unquoted following their release from escrow, converting to ordinary shares on achievement of prescribed milestones.

The company said that escrow shares were issued as part consideration to the vendors of the Mach7 business acquired in 2016 (BD: Apr 8, 2016).

Mach7 said that following the release of the shares from escrow, there were a further 397,540 shares held in voluntary escrow with a total of it would have 117,849,656 shares available for trading.

Mach7 was up half a cent or 1.75 percent to 29 cents.

### [PRESCIENT](#)

Prescient has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 9.4 percent from 9.6 cents to 10.5 cents on March 27, 2017 and noted a significant increase in trading volume.

Prescient fell 0.6 cents or six percent to 9.4 cents with 1.7 million shares traded.

### [RESAPP](#)

FIL Limited says it has increased its substantial holding in Resapp from 47,331,079 shares (7.18%) to 54,156,098 shares (8.22%).

The Hong Kong, London and Sydney-based FIL said it bought and sold shares between February 21 and March 24, 2017, at prices ranging from 32 cents and 35 cents.

Resapp was unchanged at 32.5 cents.

### [ZELDA THERAPEUTICS](#)

Zelda has requested a trading halt "pending the release of an announcement concerning a capital raising".

Trading will resume on March 30, 2017 or on an earlier announcement.

Zelda last traded at 9.8 cents.

### [UNILIFE CORP](#)

Unilife says that senior vice-president and chief commercial officer Michael Ratigan will resign from the company, effective on April 4, 2017.

Unilife said that Mr Ratigan was leaving to take a job at a private life sciences company.

Unilife was unchanged at four cents.